Combination cancer therapy with an AKT inhibitor and other anticancer agents

1. A combined anticancer agent for simultaneous, separate or successive administration in cancer therapy, comprising the following pharmaceutical preparations (a) and (b):

(a) a pharmaceutical preparation comprising 8-[4-(1-aminocyclobutyl)phenyl]-9phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent, and

(b) a pharmaceutical preparation comprising, together with a pharmaceutically acceptable carrier or diluent, at least one anticancer agent selected from the group consisting of anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors, or a pharmaceutically acceptable salt thereof, wherein

the anticancer antimetabolites are 5-fluorouracil and gemcitabine;

the anticancer antibiotics is doxorubicin;

the plant-derived anticancer agents are docetaxel and paclitaxel;

the anticancer platinum-coordinated complex compounds are cisplatin and carboplatin;

the anticancer camptothecin derivatives is camptothecin; and

the anticancer tyrosine kinase inhibitors are lapatinib and erlotinib and wherein

the cancer is selected from breast cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer and prostate cancer.

2. An anticancer agent comprising 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one or a pharmaceutically acceptable salt thereof, and at least one anticancer agent selected from the group consisting of anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors, wherein the definition of each anticancer agent is the same as defined in claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

3. A pharmaceutical kit comprising in a first compartment 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent, and in a second compartment at least one anticancer agent selected from the group consisting of anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors, wherein the definition of each anticancer agent is the same as defined in claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier or diluent.

4. A method for the treatment of cancer, which comprises administering to a subject in need thereof a therapeutically-effective amount of 8-[4-(1-aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridin-3(2H)-one or a pharmaceutically acceptable salt thereof, in combination with at least one anticancer agent selected from the group consisting of anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinated complex compounds, anticancer camptothecin derivatives and anticancer tyrosine kinase inhibitors, wherein the definition of each anticancer agent is the same as defined in claim 1 , or a pharmaceutically acceptable salt thereof.

5. The method according to claim 4 , wherein the cancer is selected from breast cancer, endometrial cancer, non-small cell lung cancer, ovarian cancer and prostate cancer.